Business Wire

Study Shows House Wellness Foods’ Breakthrough Feed LP20 ® Can Advance the Potential of Rivers and Seas to Feed Our Emerging World

Share

Vietnam is a nation that has seen its share of turmoil and suffering over the past century, and emerged from it with strength, enthusiasm, dedicated to progress and self-sufficiency. Over the past 50 years its participation on the global stage has steadily risen, with ever-increased attention to commerce, health, and education.

A recently released study on the efficacy of House Wellness Foods’ Feed LP20® in combating piscine disease factors can be seen as a glimmer of light along the pathway to Vietnam’s bright future.

As much as 35% of Vietnam’s aquacultural activity is built around river farming of the juvenile striped catfish [Pangasianodon hypophthalmus], making it the world’s largest producer of this nutritious staple, not only for its own consumption but for export to China, Europe, and elsewhere.

Vietnam’s story is one of many that expose the dual edge of farming to emerging populations. It’s been the keystone of civilization’s advancement since the dawn of humankind, but where resources are limited and need is great, farming’s potential hazards become viciously clear. Overstocked waters turn hazardous to human life due to excessive waste production and a rise in bacteria, parasites, fungi, and viruses. Overstocked waters produce fish that are increasingly malnourished, enervated, injured, and unable to reproduce.

The reflex response to this blight has been the use of antibiotics to keep weakened fish populations alive. Apart from expense, before long, disease-inducing agents mutate to resist the antibiotic, which, in turn, leads to the use of more varied antibiotics, causing a dangerous downward spiral. All the while antibiotics are entering the food chain and turning up in the human metabolic system to unpredictable, deleterious effect. Promise quickly turns to peril for the farmer, for the consumer, and for the future of vital aquaculture.

Feed LP20® can reverse this tide…

The details of this new study show its dramatic impact. In summary, researchers fed test stocks a diet supplemented with heat-killed Lactobacillus plantarum, strain L-137, the active ingredient in Feed LP20®. Key to the high effectiveness of Feed LP20® is the heat-killing process. It fully utilizes the strain’s characteristics, an area where House Wellness Foods holds an unparalleled position of authority based upon years of peer-reviewed testing and research, and continuous refinement of the development process. Heat treatment hardens bacillary cell walls and fixes their genetic material. Not only does this enable HK-L137 to resist initial breakdown in the upper gastric system, but it can be cooked, processed, stored, and administered in an aquatic environment without compromising potency. Further, both its ability to stimulate immune cytokine interleukin 12 and its shelf life far surpass that of any living lactobacillus supplement.

House Wellness Foods and the introduction of immunobiotics

Immunobiotics promote health by triggering immune responses in the mucosa. House Wellness Foods, one of Japan’s most trusted names in food production, began its exploration of immunobiotics and their ability to bolster human immune response, support liver function, and ameliorate the causes of chronic disease over three decades ago, and the culmination of their intensive research and meticulous development was their flagship Immuno-LP20®, with its active component of 20% heat-treated Lactobacillus plantarum L-137(HK-L137). This potent lactobacillus follows a dual course on assimilation. It initiates production of signal molecule IL-12 and IFN-β cells — the latter being the most important single cytokine responsible for inhibiting viral multiplication; and it subsequently stimulates T cell activity and the production of both NK and cytotoxic T (CTL) effector cells, boosting innate immunity and fostering antibody creation as an adjunct to the adaptive immune response.

House followed the worldwide success of Immuno-LP20®, with the development of Feed LP20®, an alternative to antibiotics, and to the costly, unreliable, and lengthy process of cultivating disease-resistant strains of livestock. The overarching principle of immunobiotic therapy in both land-based and aquatic livestock is that the power to fight disease already exists within every living cell of the organism. Prior to the present study, Feed LP20® proved its remarkable effectiveness in other aquatic stock, including white leg shrimp and Nile tilapia. It recently began marketing in the EU as a complementary feed for poultry, swine, and salmonid.

The proof is in the food chain

The study shows that juvenile striped catfish fed HK-L137-supplemented diets exhibited higher final weight and specific growth rate than controlled stock given ordinary feed. The fish showed higher survival rate, longer life, better feed conversion ratios, weight gain, better protein efficiency ratios, and increased reproductive capacity. Further, a test sub-group was administered a bacterial challenge mirroring a real-life scenario in Vietnamese river farms of their most devastating bacterial threat, Bacillary Necrosis Disease (BNP), caused by the bacterial agent Edwardsiella ictaluri. Part of the test group was injected with this agent, and in every case the cumulative mortality of HK L-137-supplemented groups was lower than the group fed control diet.

Fitter fish, more successful farming, greater financial stability — all of this originating from the power of Feed LP20®, comprising 20% HK-L137, to sustain health through enhanced immunity at the very cellular level. The new study shows the promise of House Wellness Foods’ Breakthrough Feed LP20®, and points to the future of a shared world that is often fragile, yet always filled with hope.

Contact information

Satoru Onoda
Onoda_Satoru@house-wf.co.jp

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CGTN: Leading With Action: China in the Fight for Carbon-Neutral Future16.4.2021 18:29:00 CEST | Press release

Climate change is not taking a break from wreaking havoc in 2020, with the joint highest global temperatures on record, rampant bushfires, the faster rates of sea level rise and the extinction of some species. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210416005435/en/ Under this circumstance, Chinese President Xi Jinping, French President Emmanuel Macron, and German Chancellor Angela Merkel held a virtual meeting Friday on climate change, ahead of the Leaders' Climate Summit on Earth Day convened by the U.S., scheduled next week. Emphasizing that he always advocates building a community with a shared future for mankind, the Chinese president voiced his willingness to strengthen cooperation with France and Germany on climate change. "Tackling climate change is a common cause for all mankind and it should not become a geopolitical bargaining chip, a target for attacking other countries, or an excuse for trade barriers," h

Colicity Inc. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about April 16, 202116.4.2021 15:30:00 CEST | Press release

Colicity Inc. (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, completed on February 26, 2021 (the “Offering”) may elect to separately trade the Class A common stock and warrants included in the units commencing on or about April 16, 2021. Any Units not separated will continue to trade on The Nasdaq Capital Market under the symbol “COLIU,” and the Class A common stock and warrants will separately trade on The Nasdaq Capital Market under the symbols “COLI” and “COLIW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A common stock and warrants. This press release shall not constitute an o

Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS16.4.2021 10:00:00 CEST | Press release

Merck, a leading science and technology company, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting showing that the investigational Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib significantly reduced blood neurofilament light chain (NfL) levels, a key biomarker of neuronal damage and inflammation, in patients with multiple sclerosis (MS). Elevated blood NfL levels have been shown to be associated with damage to neurons and inflammation and may predict future brain atrophy and disease progression. “Blood NfL is a biomarker that may allow monitoring of disease activity and treatment response, which could be less burdensome and more sensitive than other standard clinical measures for MS patients,” said Prof. Jens Kuhle, MD, PhD, Head Multiple Sclerosis Centre, University Hospital Basel. “These data provide key insights into the role evobrutinib may play in modulating the clinical course of MS and fur

IFF Presents “Learning Labs” Video Series to Demonstrate Potential of New Company15.4.2021 22:15:00 CEST | Press release

IFF (NYSE: IFF) today introduced a new “Learning Labs” video series, featuring in-depth discussions with the leadership of the company’s segments and R&D function. Each video provides a comprehensive overview of IFF’s robust portfolio and enhanced capabilities following its recently completed merger with DuPont’s Nutrition and Biosciences (“N&B”) business. The complete “Learning Labs” series can be found here: ir.iff.com/events-presentations. In addition, IFF has also provided segment-level financial detail based on 2020 pro forma results. “As a global industry leader of high-value consumer ingredients, we are pleased to provide a closer look into our capabilities, operational model and future growth potential,” said Andreas Fibig, IFF Chairman and CEO. “Stakeholder communication remains essential to IFF’s continued growth, and since combining with N&B, we have continued to explore new ways to meaningfully connect with our investors. The insights shared through our ‘Learning Labs’ seri

Algorand and BridgeTower Capital Announce Strategic Partnership15.4.2021 22:14:00 CEST | Press release

BridgeTower Capital, a global private equity firm, focusing on traditional private equity investments and blockchain and DeFi markets, announced today a partnership with Algorand. Algorand, the creator of the world’s first pure proof-of-stake foundational blockchain, is a leading blockchain technology company accelerating the convergence of decentralized and traditional finance. BridgeTower will use Algorand’s technology as the underlying blockchain solution to issuance of the BridgeTower Capital tokenized digital security. It will also use Algorand as a preferred blockchain for BridgeTower products and services. Beyond the elementary requirement of an open, public network, Algorand’s technology enables a set of high performing Layer-1 blockchains that provide security, scalability, complete transaction finality, built in privacy, Co-Chains, and advanced smart contracts. “Algorand was a clear choice given their technology, team and leadership position in the digital marketplace,” said

BridgeTower Capital Launches Security Token Pre-Offering and Announces Global Expansion With Key Partners15.4.2021 18:00:00 CEST | Press release

BridgeTower Capital, a tokenized global private equity firm, has launched a private Security Token Pre-Offering (STO) culminating 12 months of work to purposefully assemble a team of world-class partners to participate in the blockchain infrastructure and services marketplace in the rapidly growing world of decentralized finance (DeFi). BridgeTower also announced it has formed a Zurich-based entity to further expand its current offering of blockchain infrastructure products and services. BridgeTower launched its Private -STO campaign earlier this week, which provides an opportunity for accredited investors to purchase shares in the company in the form of a digital security. BridgeTower has received active participation already and is seeking to raise $200 million in this initial raise. “We are seeing a global confluence of public and private digital finance markets being fueled by the adoption of blockchain technologies. This is creating unique opportunities for those who can assemble

Cryptology Asset Group p.l.c. successfully completes a share capital increase and sale of treasury shares and reviews options for financing further growth15.4.2021 16:49:00 CEST | Press release

Cryptology Asset Group p.l.c. (ISIN: MT0001770107; Ticker: CAP), a leading European investment company for blockchain- and crypto-related business models, has successfully completed its cash capital increase by issuing 128,375 new shares and the additional sale of the entire amount of 31,625 treasury shares to institutional investors. At a fixed price of EUR 200.00 per share each, the Company will receive total gross proceeds of EUR 32.0 million, which will be used to invest in new portfolio companies from the Cryptology pipeline. The Company is also exploring the possible acquisition of crypto assets, such as Bitcoin, as part of its treasury management strategy. To finance further growth, Cryptology is also currently reviewing various options to raise additional capital, such as through the issuance of a convertible or a straight bond. ICF BANK AG has been commissioned to conduct a market review. Management will make the final financing decision based on investor feedback and the prev